[胃癌（0-IV期）患者CA 72.4与癌胚抗原、组织多肽抗原、CA 19-9、铁蛋白的预处理评估]
[Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER].
作者信息
Buda F, Aragona P, Giani G, Sisto R, Di Nardo G, Binotto F, Gangemi P, De Zerbi T, Gentile G, Papadia A
出版信息
G Ital Oncol. 1989 Apr-Sep;9(2-3):67-72.
Before surgical treatments, sera of 54 pts suffering from gastric cancer, histologically typed and clinically staged (from stage 0 to 4), were assayed to evaluate CEA, TPA, CA 19-9 and Ferritin versus a new tumoral marker called TAG-72, in order to determine the biological behaviour and the relation to the clinical stage of this last one. Starting from their results, Authors say that the new marker TAG 72 has an increasing sensibility according to the clinical stage (4 th more than 1 st), and that the association of the TAG-72 plus CEA and/or TPA is rather significant in order to evaluate the evolution of the gastric cancer than other markers.
在进行手术治疗前，对54例经组织学分型和临床分期（0至4期）的胃癌患者的血清进行检测，以评估癌胚抗原（CEA）、组织多肽抗原（TPA）、糖类抗原19-9（CA 19-9）和铁蛋白与一种名为TAG-72的新型肿瘤标志物，从而确定TAG-72的生物学行为及其与临床分期的关系。基于检测结果，作者称新型标志物TAG-72的敏感性随临床分期增加（4期高于1期），并且为评估胃癌进展，TAG-72联合CEA和/或TPA比其他标志物更具显著意义。
Zotero 插件